Initial Beneficial Ownership · 3
Nasus Pharma Ltd.
NSRXNYSE_AMERICANEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
ownership.xml
Filing details
- Report period
- 2026-09-19
- Issuer
- Nasus Pharma Ltd
- Issuer CIK
- 0002029039
- Trading symbol
- NSRX
Reporting owner 1
- Name
- Elmaliah Oren
- Reporting owner CIK
- 0001713701
- Relationship
- Officer
- Officer title
- Interim CFO
- Address
- P.O. BOX 284, TEL-AVIV-YAFO, ISRAEL, L3, 6100201
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership |
|---|---|---|---|---|---|---|
| Share options (right to buy)[F1] | 1.2264 | 2020-06-13 | 2029-11-28 | Ordinary Shares | 24,680 | D |
| Share options (right to buy)[F2] | 6.0462 | 2025-01-17 | 2035-01-17 | Ordinary Shares | 27,460 | D |
Table key
- D
- Direct
Footnotes
- F1
- Options to purchase 24,680 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 28, 2019. As of September 18, 2026, 24,680 options remain outstanding, all of which are vested and exercisable, at an exercise price of $1.2264 per share, expiring November 28, 2029.↩ 1
- F2
- Options to purchase 27,460 Ordinary Shares were granted on January 17, 2025, with the total grant vesting in equal quarterly installments of 8.33% commencing on January 17, 2025. As of September 18, 2026, 13,840 are vested and exercisable, at an exercise price of $6.0462 per share, expiring January 17, 2035.↩ 1
Signature 1
- Signed
- /s/ Oren Elmaliah
- Date
- 2026-09-23
Company context
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.